AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Intro
This chapter explores the ongoing debate over the potential reclassification of psychedelic substances for medicinal use, particularly in treating conditions like depression and PTSD. It discusses recent FDA developments regarding MDMA and emphasizes the need for further research to evaluate the benefits and risks of these substances in mental health treatment.